Neutral impactCompany

Dr. Reddy's Laboratories Limited — News Verification

NSE 1 hr ago·18 Sept 2026, 3:16 am
DR. Reddy S Laboratories

Dr. Reddy's Laboratories has confirmed that it has received a voluntary license from Gilead Sciences to manufacture and market a once-yearly HIV prevention drug in India. This authorization allows the company to produce the medication, which is currently sold under the brand name Lenacapavir, for the local market. The drug is designed to be taken twice a year, offering a significant improvement in convenience and adherence compared to daily or weekly HIV prevention options.

For investors, this development is a positive step for Dr. Reddy's. It expands the company's portfolio in the critical HIV prevention space and leverages its strong manufacturing capabilities. The move aligns with the broader trend of global pharmaceutical companies partnering with Indian firms to access local markets. Investors should monitor the company's future updates regarding the timeline for market launch and any potential regulatory approvals required in India.

Affected stocks

Neutral1 stock

DR. Reddy S Laboratories

DRREDDY Neutral

₹1,175.00

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

  • Concerns DR. Reddy S Laboratories (DRREDDY).
  • Category: Company.

Why it matters

A routine update for DR. Reddy S Laboratories. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at NSE.

More Company news

More news

Can you open multiple Post Office MIS accounts? Here’s what investors must know

Mint · 1 hr ago

Wipro launches STO360 solution to streamline outage management

Wipro₹166.40▲ 0.00%

Business Standard · 1 hr ago

Dividend alert! Last day to buy Bharat Dynamics, Dixon Tech among 55 stocks for dividends, Do you own any?

Bharat Dynamics₹1,151.90▲ 0.00%

Economic Times · 1 hr ago

Tata Sons at a crossroads: Why N Chandrasekaran’s reappointment may not end the battle

BusinessLine · 1 hr ago

Six companies debut on bourses; four deliver premium listings

Economic Times · 2 hrs ago

OnEMI Technology Solutions shares in focus after board nod to raise up to ₹832 crore via preferential issue

Onemi Technology SOL₹359.95▲ 0.00%

CNBC-TV18 · 2 hrs ago

Artemis Medicare shares gain 26% in 3 months; analysts see 30% upside

Economic Times · 2 hrs ago

Tata group shares rally on hopes of listing

Times of India · 2 hrs ago

Brookfield to invest up to $600mn in ACME's business

ACME Solar Holdings₹27.59▲ 0.00%

Times of India · 2 hrs ago

Latest headlines

More news

Six factors, 250 stocks and one model: How JioBlackRock is building portfolios

Economic Times · 1 hr ago

Bank of Japan increase interest rates at 31-year high of 1.25%

Mint · 1 hr ago

Hero Motors IPO Day 3: GMP at 7%; Check subscription status and key details. Should you subscribe?

Economic Times · 1 hr ago

Stocks Moneycontrol.com

US Yields, Crude Oil prices cool | Tata Group Stocks In Focus on Tata Sons Tata Trusts Split

Moneycontrol.com · 1 hr ago

IPO The Economic Times

Sonaselection India IPO Day 2: GMP at 7%. Check subscription status and key details

The Economic Times · 1 hr ago

HDFC Life Insurance Company among 4 stocks showing RSI trending up

HDFC Life INS CO₹557.00▲ 0.00%

Economic Times · 1 hr ago

Veegaland Developers shares to list today; Check GMP ahead of debut

Economic Times · 1 hr ago

NSE IPO Day 2: Issue subcribed 43% so far. GMP hints 8% listing pop. Check review, key dates. Should you apply or skip?

Mint · 1 hr ago

Nabfid sanctions Rs 3,000 crore-plus loans to at least four data centres as AI capex accelerates in India

Economic Times · 1 hr ago

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.